Review
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Sep 26, 2019; 11(9): 634-649
Published online Sep 26, 2019. doi: 10.4252/wjsc.v11.i9.634
Using induced pluripotent stem cells for modeling Parkinson’s disease
Minjing Ke, Cheong-Meng Chong, Huanxing Su
Minjing Ke, Cheong-Meng Chong, Huanxing Su, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao 999078, China
Author contributions: Minjing Ke and Cheong-Meng Chong contributed equally to this manuscript.
Supported by the Macao Science and Technology Development Fund, No. 039/2017/AFJ and 0020/2018/A.
Conflict-of-interest statement: The authors have declared no conflicts of interest.
Open-Access: This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Huanxing Su, MD, PhD, Associate Professor, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, University Northern Road, Macao 999078, China. huanxingsu@umac.mo
Telephone: +853-83978518 Fax: +853-28841358
Received: February 25, 2019
Peer-review started: February 27, 2019
First decision: April 11, 2019
Revised: July 26, 2019
Accepted: August 20, 2019
Article in press: August 20, 2019
Published online: September 26, 2019
Processing time: 212 Days and 0.2 Hours
Core Tip

Core tip: Human induced pluripotent stem cell (iPSC)-derived dopaminergic neurons hold great promise for studying disease mechanisms underlying Parkinson’s disease (PD) and testing drug effects. A number of reviews have previously summarized the potential use of patient iPSCs for modeling PD. However, few of them comprehensively discuss the establishment of gene-editing-based iPSCs for PD and their application in research. Our objective is to consolidate the current literature on various iPSC-based PD models either derived from PD patients through reprogramming technology or established by gene-editing technology, and provide new insights into the application of iPSC PD models.